Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform. | Neomorph is ...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

Globally, Novo Nordisk holds 65% of the market for GLP ... The company's ability to produce the next generation of weight loss medicines building on the success of Wegovy is now deeply in question.

Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, ...

Spain — one of Europe's fastest growing economies, according to the OECD — is set to publish import and export figures on ...

Fifteen drugs, including Novo Nordisk's Ozempic and Wegovy, are slated for Medicare price negotiations under the Inflation ...